Get the Stockscreener App
115.93
1.02%
-1.20
Pre-market:
115.00
-0.93
-0.80%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $115.93, with a volume of 5.32M.
It is down -1.02% in the last 24 hours and down -2.90% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$117.13
Open:
$116.69
24h Volume:
5.32M
Relative Volume:
1.18
Market Cap:
$201.34B
Revenue:
$41.22B
Net Income/Loss:
$5.77B
P/E Ratio:
39.43
EPS:
2.94
Net Cash Flow:
$6.49B
1W Performance:
+0.16%
1M Performance:
-2.90%
6M Performance:
+12.32%
1Y Performance:
+14.56%
1-Day Range:
$115.53
$116.77
1-Week Range:
$114.43
$117.94
52-Week Range:
$99.71
$121.64
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ABT | 115.93 | 201.34B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 385.68 | 146.32B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.17 | 132.22B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 84.11 | 107.39B | 33.00B | 4.29B | 5.50B | 2.71 |
| EW | 69.54 | 41.01B | 6.60B | 4.16B | 490.10M | 2.34 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - Yahoo Finance
Portfolio Design Labs LLC Has $2.12 Million Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Plant-based Beverage Market is Estimated to Reach $56.73 Billion with a 11.9% CAGR By 2034 | Fact.MR Reports - GlobeNewswire Inc.
Abbott Laboratories (NYSE:ABT) Shares Acquired by Avior Wealth Management LLC - MarketBeat
No magic with Abbott’s Amulet compared to Watchman - BioWorld Online
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
Abbott opens CGM sensor manufacturing facility in Ireland as part of $465M investment - Cardiovascular Business
Abbott opens plant in Ireland to boost Libre 3 sensor production - MedTech Dive
Abbott reports positive Amplatzer Amulet data in head-to-head trial with Boston Scientific's Watchman - Mass Device
West Family Investments Inc. Takes $544,000 Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
PNC Financial Services Group Inc. Sells 25,295 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy? - Yahoo Finance
Banque Cantonale Vaudoise Boosts Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Holdings Decreased by Wrapmanager Inc. - MarketBeat
Fifth Third Wealth Advisors LLC Buys 4,705 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Prospera Financial Services Inc Raises Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott opens new manufacturing facility for diabetes business in Ireland - Yahoo News
Abbott Laboratories (NYSE:ABT) Shares Bought by Pathstone Holdings LLC - MarketBeat
Thrivent Financial for Lutherans Has $52.22 Million Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott opens new Kilkenny site for diabetes tech - SiliconRepublic.com
Mawer Investment Management Ltd. Sells 24,407 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Opens New Diabetes Care Mfg Facility in Ireland - MPO-mag
First Western Trust Bank Lowers Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott opens new FreeStyle Libre manufacturing plant in Ireland - Mass Device
MAI Capital Management Sells 9,904 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
US medtech firm Abbott creates 800 jobs in Kilkenny - Irish Independent
Abbott Opens State-of-the-Art Global Manufacturing Facility in Kilkenny, Ireland - cnhinews.com
Swiss National Bank Purchases 26,000 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
With 77% institutional ownership, Abbott Laboratories (NYSE:ABT) is a favorite amongst the big guns - Simply Wall St
Mizuho Securities USA LLC Has $12.86 Million Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Mutual of America Capital Management LLC Has $24.39 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Sold by Mizuho Markets Americas LLC - MarketBeat
Abbott Laboratories (ABT): A Magnificent Dividend Growth Stock to Buy Now - Insider Monkey
Natixis Advisors LLC Purchases 204,478 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Sells 4,596 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Kentucky Retirement Systems Has $13.82 Million Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Ipswich Investment Management Co. Inc. Cuts Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Sold by Miramar Capital LLC - MarketBeat
Abbott extends executive agreements through 2026 By Investing.com - Investing.com Nigeria
Abbott Laboratories (ABT) Extends Executive Change in Control Ag - GuruFocus.com
Abbott Inks $8M Deal With Healthcare Fraudster In TM Suit - Law360
Abbott Laboratories stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories (NYSE:ABT) Stock Position Increased by First Long Island Investors LLC - MarketBeat
Abbott Laboratories (NYSE:ABT) Stock Holdings Increased by Simplify Asset Management Inc. - MarketBeat
Vectors Research Management LLC Makes New Investment in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Holdings Raised by CIBC Asset Management Inc - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Sold by Dearborn Partners LLC - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Sold by Curi RMB Capital LLC - MarketBeat
Victory Capital Management Inc. Trims Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):